Cadrenal Therapeutics (Cadrenal Therapeutics) EBIT per Share : $-0.33 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics EBIT per Share?

Cadrenal Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.10. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cadrenal Therapeutics's EBIT per Share or its related term are showing as below:

CVKD's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cadrenal Therapeutics's EBIT for the three months ended in Mar. 2024 was $-1.66 Mil.

Cadrenal Therapeutics EBIT per Share Historical Data

The historical data trend for Cadrenal Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics EBIT per Share Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

EBIT per Share

-0.62

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial				-0.48	-0.09	-0.07	-0.07	-0.10

Cadrenal Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cadrenal Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.34	/	13.492
=	-0.62

Cadrenal Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.663	/	16.008
=	-0.10

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.33

Cadrenal Therapeutics (NAS:CVKD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cadrenal Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029